Another fianlimab fiasco for Regeneron
The company discontinues the Lag3 project in lung cancer.
Erasca dips on patient death
ERAS-0015 data look good, but the company is punished for a pneumonitis death.
AACR 2026 – Matisse paints a mixed picture for Innate
IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
Gilead edges further away from Arcus
The disclosure comes as another of Arcus's TIGIT trials flops.
Arvinas seeks to outdo Astellas
Early data are coming with the KRAS G12D degrader ARV-806.
Henlius starts a pivotal journey to catch Pfizer
The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April.
Merck also goes for all-comers in adjuvant lung
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
Kairos expands lung resistance strategy
The company will license EGFR and cMet inhibitors from Celyn.
BioNTech's patritumab me-too advances
The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer.
